PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule for further investigation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nerviano Medical Sciences
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Metastatic hormone refractory prostate cancer progressing after docetaxel based therapy

• Adequate bone marrow, liver and kidney function

Exclusion Criteria:

• More than one prior chemotherapy line

• Uncontrolled hypertension

• Brain or leptomeningeal disease

• Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the previous 6 months